| 5.67 0 (0%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.66 | 1-year : | 7.78 |
| Resists | First : | 5.7 | Second : | 6.66 |
| Pivot price | 5.65 |
|||
| Supports | First : | 5.59 |
Second : | 5.51 |
| MAs | MA(5) : | 5.66 |
MA(20) : | 5.64 |
| MA(100) : | 4.76 |
MA(250) : | 3.87 |
|
| MACD | MACD : | 0  |
Signal : | 0.1 |
| %K %D | K(14,3) : | 63.1 |
D(3) : | 65.7 |
| RSI | RSI(14): 64.3 | |||
| 52-week | High : | 6.27 | Low : | 1.94 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SCPH ] has closed below upper band by 25.8%. Bollinger Bands are 92.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.68 - 5.71 | 5.71 - 5.73 |
| Low: | 5.6 - 5.63 | 5.63 - 5.66 |
| Close: | 5.63 - 5.67 | 5.67 - 5.71 |
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Tue, 07 Oct 2025
Over $370M Annualized Run Rate — MannKind Completes Acquisition of scPharmaceuticals; $5.35 Cash - Stock Titan
Tue, 07 Oct 2025
MannKind completes acquisition of scPharmaceuticals; SCPH to be delisted from Nasdaq - Investing.com
Thu, 25 Sep 2025
scPharmaceuticals Issues Promissory Note to MannKind - TipRanks
Mon, 25 Aug 2025
MannKind Corporation to Acquire scPharmaceuticals: More Details Inside - Stocktwits
Mon, 25 Aug 2025
MannKind to acquire scPharmaceuticals for up to $6.35 per share - Investing.com
Mon, 25 Aug 2025
scPharmaceuticals Surges Amid Patent Approvals and Revenue Growth - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 5.9 (%) |
| Held by Institutions | 80.3 (%) |
| Shares Short | 812 (K) |
| Shares Short P.Month | 1,340 (K) |
| EPS | -1.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.41 |
| Profit Margin | -183.6 % |
| Operating Margin | -89.2 % |
| Return on Assets (ttm) | -57.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 99.1 % |
| Gross Profit (p.s.) | 0.63 |
| Sales Per Share | 0.93 |
| EBITDA (p.s.) | -1.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -66 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -3.14 |
| PEG Ratio | 0 |
| Price to Book value | -14.18 |
| Price to Sales | 6.09 |
| Price to Cash Flow | -4.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|